Page last updated: 2024-09-05

sorafenib and tqx 173

sorafenib has been researched along with tqx 173 in 1 studies

Compound Research Comparison

Studies
(sorafenib)
Trials
(sorafenib)
Recent Studies (post-2010)
(sorafenib)
Studies
(tqx 173)
Trials
(tqx 173)
Recent Studies (post-2010) (tqx 173)
6,5207305,251501

Protein Interaction Comparison

ProteinTaxonomysorafenib (IC50)tqx 173 (IC50)
Glutamate receptor 1Mus musculus (house mouse)2.3
Glutamate receptor 2Mus musculus (house mouse)2.3
Glutamate receptor 1Homo sapiens (human)2.3
Glutamate receptor 2Homo sapiens (human)2.3
Glutamate receptor 3Homo sapiens (human)2.3
Glutamate receptor 4Homo sapiens (human)2.3
Glutamate receptor 4Mus musculus (house mouse)2.3
Glutamate receptor 3Mus musculus (house mouse)2.3

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's0 (0.00)24.3611
2020's1 (100.00)2.80

Authors

AuthorsStudies
Bai, R; Jiang, X; Wu, K; Zhang, P; Zhang, Y1

Reviews

1 review(s) available for sorafenib and tqx 173

ArticleYear
Functionalized quinoxalinones as privileged structures with broad-ranging pharmacological activities.
    European journal of medicinal chemistry, 2022, Feb-05, Volume: 229

    Topics: Animals; Anti-Allergic Agents; Anti-Bacterial Agents; Anti-Infective Agents; Anti-Inflammatory Agents; Antineoplastic Agents; Antioxidants; Antiviral Agents; Drug Development; Heterocyclic Compounds; Humans; Hypoglycemic Agents; Mice; Neuroprotective Agents; Photochemotherapy; Quinoxalines; Structure-Activity Relationship; Tubulin Modulators

2022